National Health Investors price target raised to $81 from $77 at Truist

Truist raised the firm’s price target on National Health Investors (NHI) to $81 from $77 and keeps a Buy rating on the shares. The firm cites the company’s Q2 earnings beat and raise, along with the encouraging outlook from its management, the analyst tells investors in a research note. Truist is projecting healthy earnings growth, supported by the 2026-end rent reset for National Healthcare Corporation and an attractive investment yield spread over the company’s cost of capital.